SCHEMBL4859263

SCHEMBL4859263

Cc1nc(NCCO)c2ccccc2n1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.64
PGK1 P00558 1/20 0.63
TAAR1 Q96RJ0 3/20 0.61
HTT P42858 3/20 0.61
POLB P06746 2/20 0.61
SMN1; SMN2 Q16637 1/20 0.61
KDM4E B2RXH2 3/20 0.59
SLC2A1 P11166 1/20 0.59
LMNA P02545 3/20 0.58
ALDH1A1 P00352 3/20 0.58
RAD52 P43351 3/20 0.58
GAA P10253 2/20 0.58
MITF O75030 1/20 0.58
TTR P02766 1/20 0.58
GLA P06280 1/20 0.58
RAB9A P51151 1/20 0.58
KMT2A Q03164 3/20 0.57
PKM P14618 1/20 0.57
GBA1 P04062 1/20 0.57
CYP2C19 P33261 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4859009 0.86 LATS1 (0.49) MAPK1PGK1TAAR1HTTPOLB
SCHEMBL16404321 0.83 MAPK1 (0.82) MAPK1PGK1TAAR1HTTPOLB
SCHEMBL4856835 0.83 APP (0.69) MAPK1HTTSMN1; SMN2KDM4ELMNA
SCHEMBL13381601 0.81 PDE5A (0.57) HTTSMN1; SMN2KDM4ELMNAALDH1A1
SCHEMBL7337304 0.81 APP (0.70) MAPK1PGK1TAAR1HTTPOLB
SCHEMBL5107692 0.80 MAPK1 (0.59) MAPK1PGK1TAAR1HTTPOLB
SCHEMBL4866356 0.80 MAPK1 (0.59) MAPK1PGK1TAAR1HTTPOLB
SCHEMBL4866885 0.79 GBA1 (0.59) HTTLMNAALDH1A1GBA1CYP2C19
SCHEMBL3977315 0.79 RAD52 (0.71) HTTSMN1; SMN2KDM4ELMNAALDH1A1
SCHEMBL11260828 0.78 GBA1 (0.60) MAPK1HTTSMN1; SMN2KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2008-08-28 US claimed
JP-2008526734-A 2008-07-24 JP claimed
EP-1844023-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2007-10-17 EP claimed
WO-2006071095-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2006-07-06 WO claimed
WO-2024123968-A1 RNA TARGETING COMPOUNDS AND USES THEREOF RANAR THERAPEUTICS, INC. (US) 2024-06-13 WO disclosed
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2008-08-28 US disclosed
EP-1844023-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2007-10-17 EP disclosed
WO-2006071095-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2006-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY GPR119, GCKR, GLP1R MAPK1 513/4885PGK1 219/4885TAAR1 3444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.